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• Antiviral Resistance is a leading cause of 
HIV treatment complications in the US
• Understanding resistance rate and type 
in an area can help guide treatment 
plans and assess prevention program 
effectiveness
• Resistance variation between cities is 
understudied
• Do intervention programs work? Is there 
geographic variation?
Methods
• Retrieved Protease sequences from Los 
Alamos HIV Sequence Database 
• Selected sequences from Washington 
DC, Boston, New York, San Diego, and 
Seattle
• Analyzed aligned sequences for 
mutations with HIVdb + R
• collected information showing the 
common types of mutations in each city 
and the number of mutations per year in 
each city 
Results + Discussion
• Significant differences in most common 
resistance mutations dependent on city
• This suggests a possible relationship 
between HIV population genetics and 
geographic location 
• Future Directions: further research 
involving a greater sample size, patient 
tracking
• geographic personalized medicine
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